Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05627375 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

Study acronym: BAT-VTE
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Mar 5, 2024, no change to tracked fieldsv5-v7
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 2023 to Aug 16, 2023 · Study description expanded, about 279 words · Site details revised at 28 of 28 sitesv4 Show 3 more changesShow less
    • Start date changed from estimate of May 2023 to Aug 16, 2023
    • Study description expanded, about 279 words
    • Site details revised at 28 of 28 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Start date: Mar 2023 to May 2023 Secondary endpoints revised (6) · Study description shortened, about 124 words · Study title shortened, about 2 wordsv3 Show 3 more changesShow less
    • Secondary endpoints revised (6)
    • Study description shortened, about 124 words
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Jan 2023 to Mar 2023 Secondary endpoints revised (6)v2 Show 1 more changeShow less
    • Secondary endpoints revised (6)

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients. Their management requires use of antithrombotic agents: anticoagulant therapy (AC) for secondary prevention of VTE recurrence, antiplatelet (AP) for secondary prevention of major adverse ischemic cardiovascular and cerebrovascular event (MACCE) in patients with atherosclerotic cardiovascular disease (coronary artery disease, atherosclerotic cerebrovascular disease, lower extremity peripheral arterial disease). Side effects of antithrombotic drugs are the 1st cause of emergency admission and hospitalization for an adverse drug reaction (mainly bleeding), and the combination of AC with AP strongly increases this risk.
Trial Details
NCT Number NCT05627375
Lead Sponsor Centre Hospitalier Universitaire de Saint Etienne
Collaborators: Ministry of Health, France
Conditions Venous Thromboembolic Disease
Enrollment 1,400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov